KURA May 2024 17.500 put
| Previous close | 0.4200 |
| Open | 0.4800 |
| Bid | 0.0000 |
| Ask | 1.0500 |
| Strike | 17.50 |
| Expiry date | 2024-05-17 |
| Day's range | 0.4200 - 0.4800 |
| Contract range | N/A |
| Volume | |
| Open interest | 101 |
GlobeNewswireKura Oncology to Participate in Bank of America Securities Healthcare Conference
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Bank of America Securities 2024 Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 1:40 p.m. ET / 10:40 a.m. PT on May 15, 2024. A live audio webcast of the f
Insider MonkeyKura Oncology, Inc. (NASDAQ:KURA) Q1 2024 Earnings Call Transcript
Kura Oncology, Inc. (NASDAQ:KURA) Q1 2024 Earnings Call Transcript May 4, 2024 Kura Oncology, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, ladies and gentlemen, and welcome to the Q1 2024 Kura Oncology Financial Results Conference Call. […]
- GlobeNewswire
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 03, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on May 1, 2024, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 67,950 shares of common stock to six (6) new employees under the
